--- title: "Invivyd (IVVD) news: offering" url: "https://aibio.space/companies/invivyd/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "IVVD offering news: Invivyd prices offering of 74,811,404 shares at $0.52 each. Invivyd, Inc. (NASDAQ: IVVD), United States." --- IVVD Invivyd, Inc. NASDAQ · United States # Invivyd (IVVD) news IVVD offering news Financings · 2025-08-20 ## [Invivyd prices offering of 74,811,404 shares at $0.52 each](https://aibio.space/news/invivyd-prices-offering-74-811-404-shares-0-52-each/) Invivyd sold 74,811,404 shares at $0.52 each and pre-funded warrants for up to 21,342,442 more shares, for a total public offering price of $49,997,865.68 before underwriting discounts. ## Latest Invivyd news 1. 2025-04-21 Debt Financing [Invivyd signs term loan facility of up to $30 million with Silicon Valley Bank](https://aibio.space/news/invivyd-signs-term-loan-facility-up-30-million-silicon-valley-bank/) Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, can lend Invivyd up to $30 million in three tranches. Only the first $10 million is open without revenue milestones, and the loans are due March 1, 2029. ## Invivyd at a glance - **Ticker**: IVVD - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $160.1 million ### Related companies - [Traws Pharma](https://aibio.space/companies/traws-pharma/) NASDAQ: TRAW - [Contineum Therapeutics](https://aibio.space/companies/contineum-therapeutics/) NASDAQ: CTNM - [Dyne Therapeutics](https://aibio.space/companies/dyne-therapeutics/) NASDAQ: DYN - [Lakewood-Amedex Biotherapeutics](https://aibio.space/companies/lakewood-amedex-biotherapeutics/) NASDAQ: LABT - [OS Therapies](https://aibio.space/companies/os-therapies/) AMEX: OSTX - [TScan Therapeutics](https://aibio.space/companies/tscan-therapeutics/) NASDAQ: TCRX - [ThermoGenesis Holdings](https://aibio.space/companies/thermogenesis/) OTC: THMO - [LianBio](https://aibio.space/companies/lianbio/) OTC: LIANY ### Also on NASDAQ - [Dermata Therapeutics](https://aibio.space/companies/dermata-therapeutics/) DRMA - [AgomAb Therapeutics NV](https://aibio.space/companies/agomab-therapeutics/) AGMB - [ESTABLISHMENT LABS HOLDINGS INC.](https://aibio.space/companies/establishment-labs/) ESTA - [Entera Bio](https://aibio.space/companies/entera-bio/) ENTX - [Bicycle Therapeutics](https://aibio.space/companies/bicycle-therapeutics/) BCYC - [60 Degrees Pharmaceuticals](https://aibio.space/companies/60-degrees-pharmaceuticals/) SXTP ## What Invivyd does Invivyd is a biopharmaceutical company focused on monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases, beginning with SARS-CoV-2, the virus that causes COVID-19. It aims to expand into other high-need indications such as respiratory syncytial virus (RSV) and measles. Its first authorized mAb, PEMGARDA (pemivibart), received an emergency use authorization from the FDA in March 2024 for pre-exposure prophylaxis of COVID-19 in adults and adolescents with moderate-to-severe immune compromise. Its next-generation candidate, VYD2311, was engineered from adintrevimab, and positive full Phase 1/2 data were announced in June 2025. The FDA granted Fast Track designation for VYD2311 for prevention of COVID-19 in people with underlying risk factors for progression to severe disease. The Phase 3 DECLARATION trial began in December 2025, with top-line data anticipated in mid-2026. In February 2026 the company announced FDA alignment on the Phase 3 LIBERTY trial, which tests VYD2311 alone and with an mRNA COVID vaccine. It also selected VBY329, a candidate for RSV prevention in neonates, infants and children, in November 2025, and relies on WuXi Biologics as its contract manufacturer for chemistry, manufacturing and controls work. | Product or program | What it is | Stage | |---|---|---| | PEMGARDA (pemivibart) | Monoclonal antibody for pre-exposure prophylaxis of COVID-19 in immunocompromised people | Emergency use authorized, March 22, 2024 | | VYD2311 | Next-generation COVID-19 monoclonal antibody for prevention | Phase 3 DECLARATION started December 2025; Fast Track designation | | LIBERTY trial (VYD2311) | VYD2311 alone and with an mRNA COVID vaccine | Phase 3; FDA alignment announced February 2026 | | VBY329 | Monoclonal antibody for RSV prevention in neonates, infants and children | Selected November 2025; IND readiness targeted second half of 2026 | Summarised from the company's [10-K filed Mar 5, 2026](https://www.sec.gov/Archives/edgar/data/1832038/000119312526092547/ivvd-20251231.htm). ## Invivyd annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$53.4 million](https://www.sec.gov/Archives/edgar/data/1832038/000119312526092547/) | [$25.4 million](https://www.sec.gov/Archives/edgar/data/1832038/000119312526092547/) | | Research and development | [$38.3 million](https://www.sec.gov/Archives/edgar/data/1832038/000119312526092547/) | [$137.3 million](https://www.sec.gov/Archives/edgar/data/1832038/000119312526092547/) | | Net income (loss) | [-$52.5 million](https://www.sec.gov/Archives/edgar/data/1832038/000119312526092547/) | [-$169.9 million](https://www.sec.gov/Archives/edgar/data/1832038/000119312526092547/) | | Cash from operations | [-$58.1 million](https://www.sec.gov/Archives/edgar/data/1832038/000119312526092547/) | [-$170.5 million](https://www.sec.gov/Archives/edgar/data/1832038/000119312526092547/) | | Cash and equivalents | [$226.7 million](https://www.sec.gov/Archives/edgar/data/1832038/000119312526349215/) | [$69.3 million](https://www.sec.gov/Archives/edgar/data/1832038/000119312526092547/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $160.1 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Invivyd Has Invivyd raised money recently? Our latest story on this, dated Aug 20, 2025: "Invivyd prices offering of 74,811,404 shares at $0.52 each". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/invivyd-prices-offering-74-811-404-shares-0-52-each/). What is the ticker symbol of Invivyd? Invivyd, Inc. trades under the ticker IVVD on NASDAQ. Where is Invivyd listed? Invivyd, Inc. is listed on NASDAQ. What is the SEC CIK of Invivyd? The SEC Central Index Key (CIK) for Invivyd, Inc. is 1832038. Its filings are on SEC EDGAR. How many shares does Invivyd have outstanding? 294,758,746 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Invivyd listed under? Our directory records Invivyd, Inc. under United States. What does Invivyd do? Our directory classifies Invivyd, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Invivyd? The ISIN recorded for Invivyd, Inc. is US00534A1025. Does aibio.space cover Invivyd? aibio.space lists Invivyd, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Invivyd incorporated? SEC records list its state or country of incorporation as DE. What does Invivyd develop? Invivyd is a biopharmaceutical company focused on monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases, beginning with SARS-CoV-2, the virus that causes COVID-19. It aims to expand into other high-need indications such as respiratory syncytial virus (RSV) and measles. What is PEMGARDA (pemivibart) from Invivyd? PEMGARDA (pemivibart): Monoclonal antibody for pre-exposure prophylaxis of COVID-19 in immunocompromised people Stage: Emergency use authorized, March 22, 2024. What is VYD2311 from Invivyd? VYD2311: Next-generation COVID-19 monoclonal antibody for prevention Stage: Phase 3 DECLARATION started December 2025; Fast Track designation. What was Invivyd's revenue last year? $53.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Invivyd profitable? Invivyd, Inc. reported a net loss of $52.5 million for the fiscal year ended Dec 31, 2025, and used $58.1 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Invivyd Members talk about Invivyd (IVVD). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Invivyd, newest first. Each line links the filing it comes from. 1. 2026-07-24 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1832038/000119312526316066/ivvd-20260723.htm) 2. 2026-03-05 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1832038/000119312526092547/ivvd-20251231.htm) 3. 2025-11-17 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1832038/000119312525284616/d835559d424b5.htm) 4. 2025-10-02 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1832038/000119312525228321/d28850ds3.htm) 5. 2025-09-24 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1832038/000119312525215541/ivvd-ex99_1.htm) 6. 2025-08-20 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1832038/000119312525184075/d83346d424b5.htm) 7. 2025-04-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1832038/000095017025058705/ivvd-20250421.htm) 8. 2025-02-24 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1832038/000095017025025227/ivvd-ex99_1.htm) 9. 2024-12-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1832038/000095017024140800/ivvd-20241227.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:IVVD on TradingView](https://www.tradingview.com/symbols/NASDAQ-IVVD/). ## SEC filings and registration - **SEC name**: Invivyd, Inc. - **CIK**: 1832038 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: IVVD (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 205 CHURCH STREET, NEW HAVEN, CT - **Phone**: (781) 819-0080 - **Shares outstanding**: 294,758,746 as of 2026-07-30 (10-Q filed 2026-08-13) - **Former names**: Adagio Therapeutics, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1832038/000119312526406007/ivvd-20260929.htm) filed 2026-09-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1832038/000119312526377493/ivvd-20260830.htm) filed 2026-09-01 - [10-Q](https://www.sec.gov/Archives/edgar/data/1832038/000119312526349215/ivvd-20260630.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1832038/000119312526349193/ivvd-20260813.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1832038/000119312526316066/ivvd-20260723.htm) filed 2026-07-24 - [8-K](https://www.sec.gov/Archives/edgar/data/1832038/000119312526295539/ivvd-20260706.htm) filed 2026-07-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1832038/000119312526230731/ivvd-20260519.htm) filed 2026-05-19 - [10-Q](https://www.sec.gov/Archives/edgar/data/1832038/000119312526222779/ivvd-20260331.htm) filed 2026-05-14 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001832038), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Invivyd, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker IVVD, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Invivyd, Inc. - **Ticker**: IVVD - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US00534A1025 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-IVVD/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/invivyd/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Invivyd (IVVD) news: offering", 2026-10-31, https://aibio.space/companies/invivyd/